THE BI-0115 DIARIES

Hepatic impairment No dose adjustment is required in individuals with gentle or reasonable (Baby-Pugh A or B) hepatic impairment (see portion five.2). Publicity to midostaurin and its Lively metabolite CGP62221 is significantly lessen in patients with serious hepatic impairment than that in individuals with regular hepatic perform (see segment five